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Abstract: The endonucleolytic activity of human apurinic/apyrimidinic endonuclease (AP endo, Ape1) is 
a major factor in the maintenance of the integrity of the genome. On the other side, as an undesired 
effect, Ape1 overexpression has been linked to resistance to radio- and chemo-therapy treatments in 
several human tumors. Inhibition of Ape1 using siRNA or the expression of a dominant-negative form of 
the protein have been shown to sensitize cells to DNA-damaging agents, including various 
chemotherapeutic agents. Therefore, inhibition of the enzymatic activity of Ape1 might result in a potent 
antitumor therapy. Small molecules have been described as Ape1 inhibitors; yet, those compounds are 
in an early stage of development. Here we report for the first time the identification of new compounds as 
potential Ape1 inhibitors by using docking-based virtual screening technique. Some of these identified 
compounds are shown to be active in vitro with activities in the low to the medium micromolar range. 
Interaction of these compounds with Ape1 protein was observed by mass spectrometry. These 
molecules also potentiate the cytotoxicity of the chemotherapeutic agent methylmethane sulfonate in 
fribrosarcoma cells. This study demonstrate the power of the docking and virtual screening techniques 
as a first step for potential drugs design and opens the door to the development of a new generation of 
Ape1 inhibitors. 
 
Introduction 
Chemo- and radio-therapy are the two main currently available treatments to improve outcomes in 
cancer patients. The cytotoxicity of many of these agents is directly related to their propensity to induce 
genomic DNA damage.[1] The persistence of unrepaired DNA damage results in accumulation of 
mutations, cell cycle arrest and apoptosis.[2] However, the ability of cancer cells to recognize this 
damage and initiate DNA repair is an important mechanism that impacts negatively upon therapeutic 
efficacy.[3]  
The base excision repair (BER) pathway is the major mechanism for dealing with a variety of lesions 
in DNA produced by alkylating agents. This pathway is initiated by specific DNA glycosylases, which 
recognize and excise the damaged base to generate an apurinic/apyrimidinic (AP) site. Ap 
endonuclease 1 (Ape1) cleaves the phosphodiester backbone adjacent to the 5’ side of the AP site, 
generating a 3’ hydroxyl and 5’-deoxy ribose phosphate termini.[4] Polymerase β removes the 5’-deoxy 
ribose phosphate, fills in the one-nucleotide gap, and the consequent nick is ligated by DNA ligase I or 
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by DNA ligase III/XRCC1.[5] Ape1 is a fundamental protein in this essential repair pathway and it is 
thought to be responsible for 95% of total AP endonuclease activity in human cell lines.[6] In addition to 
its DNA repair activity, Ape1 acts as a redox factor for a variety of important transcription factors such as 
NF-κappaB, p53, c-Fos and c-Jun.[7] The DNA repair and the redox activities of Ape1 are distinct, both 
structurally and functionally. 
Ape1 protein levels and intracellular distribution have been related to the pathogenesis of several 
human tumors[5a, 8] and its expression pattern appears to have a prognostic significance in cancer cells, 
including breast,[8b] lung,[9] ovarian,[8e] gastro-oesophageal[10] and pancreatico-biliary[10] and bone[11] 
tumors. For this reason, several preclinical and clinical studies have suggested that Ape1 may be an 
attractive target for anticancer drug development. Using either antisense oligonucleotides or RNA 
interference approaches, different groups have reported that depletion of intracellular Ape1 sensitizes 
mammalian cells to a variety of DNA-damaging agents.[5a, 12] In pancreatic cancer cell lines for example, 
downregulation of Ape1 potentiated the cytotoxicity of gemcitabine.[13] Ape1 downregulation has also 
been shown to block ovarian cancer cell growth.[14] In melanoma and colon cell lines, Ape1 
downregulation led to an increase in apoptosis,[2a, 15] whereas its overexpression conferred protection 
from cisplatin- or H2O2-induced apoptosis.[15] Attempts to create Ape1 knockout mice were embryonically 
lethal, suggesting that Ape1 is crucial for embryonic development.[16] Heterozygous Ape1 mice were 
viable but abnormally sensitive to oxidative stress and prone to cancer progression.[17] 
Recently, there has been a significant effort towards identifying inhibitors of DNA repair proteins in 
keeping with the emerging concept that sensitizing cancer tissue to core chemotherapeutic regimens by 
simultaneous targeting DNA repair may result in enhanced treatment outcomes.[18] As a result of the 
promising therapeutic potential of the inhibition of Ape1 DNA repair activity, several reports have 
described the identification and characterization of small molecules that inhibit its repair endonuclease 
activity,[19] including methoxyamine (MX), lucanthone and 7-nitroindole-2-carboxilic acid (NCA). All three 
compounds were able to enhance the effects of methylmethane sulfonate (MMS) or temozolamida 
(TMZ) in ovarian,[20] breast,[20b, 21] colon[22] and HT1080 fibrosarcoma cancer cells.[23] In addition, 
Lucanthone was able to potentiate the effects of radiation therapy in patients with brain metastasis.[24] 
However, the evidence of lucanthone topoisomerase inhibitory activity raised a concern regarding an off-
target effect[25] and the synergistic cell killing effects observed by NCA with TMZ or MMS were unclear, 
as recent data showed that its specificity for Ape1 is controversial.[20b, 26] Using a fluorescence-based 
high-throughput assay, Kelley and co-workers described the identification of 2,4,9-
trimethylbenzo[b][1,8]napthyridin-5-amine (AR03), which was found to be active in the low micromolar 
range in vitro against purified Ape1 and inhibited AP site incision activity and its repair in SF67 
glioblastoma cells.[27] 
Other groups using high-throughput screening (HTS) approaches reported Ape1 inhibitors including 
compounds containing arylstibonic[28] or bis-carboxilic[acid.[29] Reactive Blue 2, 6-hydroxyl-DL-DOPA and 
myricetin.[30] The bis-carboxilic acid derivatives were not tested in cell based assays,[29] and no 
information about its in vivo activity can be inferred. The arilstibonic acid compounds effectively inhibited 
Ape1 in vitro but were ineffective in vivo due to poor cellular uptake.[28] Moreover, antimony-containing 
compounds are generally considered from a probe development standpoint due to their possible 
promiscuity akin to the effect of heavy metal ions and their occasional high toxicity.[31] Reactive Blue 2, 6-
hydroxyl-DL-DOPA and myricetin were found to have numerous other targets besides Ape1 in cells, 
therefore they are no such promising agents with selectivity or specificity as Ape1 inhibitors.[30]  
We have recently developed a flexible, fully automated virtual screening computational platform 
(VSDMIP)[32] to identify inhibitors of protein targets from libraries of millions of compounds. This 
computational platform has been successfully applied to the discovery of new inhibitors of the DNA 
repair protein O6-alkylguanine DNA alkyltransferase[33] and in the development of small molecules that 
compete with ubiquitin E2 variant for its interactions with ubiquitin-conjugating enzyme UBC13, inhibiting 
its enzymatic activity,[34] among others.  
Here we report the identification of novel Ape1 inhibitors by docking-based virtual screening technique. 
The activity of these compounds has been experimentally proved both in vitro and in vivo. These 
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molecules are promising lead candidates to establish quantitative structure-activity relationship models 
for further development of clinically relevant Ape1 inhibitors as coadjuvants in cancer chemotherapy. 
 
Results and Discussion 
 
Virtual screening (VS)  
The virtual screening protocol employed here is summarized in Scheme 1 and briefly described in the 
Methods section. An essential part of the procedure is to characterize the shape of the active site. For 
this purpose we used GAGA algorithm (see Methods) to obtain a sort of a negative image of the binding 
site (Figure 1). Overall, the shape of the active site does not undergo significant conformational changes 
even after binding to the DNA, as very low RMSD values were obtained after superimposing the different 
Ape1 structures deposited in the PDB. This fact is reassuring taking into account that the protein 
flexibility is not explicitly considered during the docking process. The active site is a well-defined deep V-
shaped cleft, with a Mg2+ cation located in its “elbow”. 
 Upon characterizing the binding site, a library of around 4 million (4,039,777) compounds was first 
screened using DOCK[35] and the negative image of the binding site. We apply a ZScore (see Methods) 
cut off value of 4 on the DOCK ranked list, and a set of 2,288 molecules passed onto the next step. 
These molecules were then re-docked with CDOCK[36] and scored with its molecular mechanics energy 
function which specifically includes solvent and hydrogen bonding terms. The 100 highest scoring 
compounds were submitted to MD simulation in explicit solvent and their binding energies estimated and 
pair-wise decomposed by MM-GBSA[37] calculation over a large collection of snapshots homogenously 
sampled along the trajectories.  
 Finally, from the top scoring compounds, and upon visual examination, 15 candidates were selected, 
were purchased, and tested experimentally. For those showing in vitro activity against Ape1, the MM-
GBSA[37]method was used to estimate free energy of binding from molecular dynamic trajectories. The 
physico-chemical properties of the molecules as stored in the ZINC database[38] are shown in Table 1.  
 
Ape1 endonuclease in vitro assays 
The 15 top-ranked compounds selected from the VS computations where purchased and dissolved in 
DMSO. The ability of those 15 candidates to inhibit the recombinant Ape1 activity in vitro was 
determined by a fluorescence-based assay described by different groups.[23, 28] In brief, a double 
stranded DNA (dsDNA) substrate was used containing in one of the strands an internal ribitol (THF) AP 
site mimic[39] and a 5’6-carboxyfluorescein (FAM) label, while the complementary strand was labeled with 
a 3’dabcyl fluorescence quencher moiety. The close proximity of the fluorophore and the quencher 
results in a dampened signal upon light excitation. Following DNA backbone cleavage by Ape1, a short 
single-stranded DNA fragment 5’-tagged with the FAM group is released from the duplex DNA substrate, 
resulting in an increase in the fluorescence. Since assay variability is to be expected, we included as a 
comparative control a compound which was previously described as Ape1 inhibitor (data not shown).[28] 
Ape1 (at 5.9 nM concentration) was incubated with the dsDNA at 37 ºC for 30 min in the presence of 
each of the 15 compounds selected during the VS at concentrations of 100 and 200 µM. The results of 
this first assay showed that compounds 11 to 15 did not exhibit any inhibitory action against Ape1 at 
these concentrations (Table 1). Compounds 7 to 10 showed an inhibitory effect versus Ape1 at 
concentration between 150 and 200 µM and were not further evaluated.  
 On the other hand, compounds 1 to 6 showed inhibitor activity at concentrations below 100 µM and 
were further analyzed in order to determine the concentration dependence for the inhibition of Ape1 
endonuclease activity. All of them inhibited Ape1 with IC50 values in the low to medium micromolar range. 
Compounds 1 and 2 were identified as the most potent inhibitors of Ape1 with an IC50 of 2.9 and 5 µM 
respectively. These two lead compounds had comparative or slightly higher effects in blocking Ape1 
activity than thiolactomycin, methyl 3, 4-dephostatin and better than other compounds found by 
Simeonov and co-workers[30]. Compounds 3 and 4 had an intermediate effect (IC50 between 16- 39 µM), 
whereas compounds 5 and 6 were weakly active showing an IC50 >50 µM. This result suggests that 
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compound 3 and 4 may partially interact with Ape1 through its methoxylphenyl group and that the 
substitution in meta position of the phenyl ring is better tolerated than in para. The resultant IC50 values 
obtained for all active compounds are shown in Table 2 and in Figure 2. The chemical structures of 
these compounds are shown in Figure 3, prioritized by low µM IC50 value. 
 
DNA Intercalation binding  
To test if these compounds inhibit Ape1 activity via non-specific DNA binding rather than by direct 
inhibition of the enzymatic activity, we employed a fluorescent dye displacement assay.[30, 40] Briefly, if a 
compound acts non-specifically by association with DNA, it would displace a DNA-bound fluorophore like 
Thiazole Orange (ThO) or ethidium bromide. As these molecules emitted fluorescence upon intercalation 
to DNA, its displacement should produce a decrease in the fluorescence of the complex dye-DNA when 
increasing amounts of the compounds were added. We selected ThO which binds non covalently to DNA 
with high affinity instead of ethidium bromide, due to the fact that its fluorescence excitation and 
emission are red-shifted, which ensures a reduced susceptibility to compound autofluorescence.[30] As 
shown in Figure 4, compounds 1 to 6 did not displace bound ThO at any range of concentrations starting 
from 100 pM to 100 µM. This result suggests that these molecules do not inhibit the Ape1 DNA repair 
activity by a non-competitive effect such as DNA-binding. In contrast, mitoxantrone, described in 
Simeonov et al[30] as a DNA-binding compound, was able to displace ThO producing a 100% decrease in 
fluorescence in the same concentration range.  
 
Complex formation detected by Mass spectrometry 
Electrospray ionization mass spectrometry (ESI-MS) has become an established tool for the 
investigation of macromolecular complexes.[41] ESI is a gentle ionization method, allowing the analysis of 
proteins without causing internal fragmentation of the molecule. Their typical multiply charged ions result 
in low mass-to-charge values which allow an accurate mass determination.[42] The non covalent complex 
formation of Ape1 with compounds 1 to 6 was analyzed by this means. The mass spectrum of Ape1 
alone exhibited a characteristic series of multiply charged positive ions (Figure 5A.a). A narrow range of 
charge state is a good indication that Ape1 has retained its folded or native conformation. Moreover, the 
ion mobility measurements further confirmed that the protein was folded during the nano ESI-MS 
experiments.  
 The direct observation of the protein-ligand complex ion can be easily achieved for tight binding 
complexes. However, weakly bound complexes, particularly those dependent on hydrophobic effects, 
are fragile and may dissociate during desolvation,[43] as we observed with compounds 2, 3 and 4 (data 
not shown). The mass spectra of Ape1 in complex with compound 5 (Figure 5A.b) showed that, although 
any evidence of the complex peaks can be observed, the free protein peaks shifted to a higher mass-to-
charge value and this fact may indicate an inhibitor-protein interaction. In the mass spectrum of Ape1 in 
presence of compounds 1 and 6, a clear signal of complex formation was observed. Figures 5A.c and 
5A.d show the ESI-MS spectra peaks corresponding to free protein (P) and protein in complex with 
ligand (PL). The complex peaks are zoomed in figure 5B. The estimated stoichiometry of the complex 
between Ape 1 and the three studied compounds (1, 5 and 6) respectively was equimolar (1:1). 
 
Docking binding modes 
For these compounds showing in vitro activity against Ape1 the binding mode was estimated by the MM-
GBSA[37]method. The binding mode of compound 2 with Ape1 highlights the interaction with the metallic 
cation, which is the most important energetically. The hydrogen bonding pattern is represented in Figure 
7. These interactions were established between: (a) the nitro group of compound 2 and the backbone 
NH group of residue Asn174; and (b) an oxygen atom from the sulphonyl moiety and the amino group 
from the side chain of residue Asn212 on the one hand, and the NHε group of residue His309, on the 
other hand. This binding mode also presented a network of hydrophobic contacts surrounding the 
quinoxaline core of compound 2 with Phe266, Trp280, and Leu282, and an additional stacking 
interaction with Tyr269, which stabilizes the benzylpyridinium moiety.  
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 The other 5 active compounds have in common a carboxylic moiety which also presented their main 
interaction with Ape1 through the Mg2+ cation. However, and compared to compound 2, this interaction is 
somehow skewed. This fact allows a gradual contribution to the stability of the complex from a salt 
bridge that is formed between the carboxylic moiety and the side chain of residue Lys98, which in turns 
depends on the position of the Mg2+ cation. Nevertheless, rather similar interaction energies were 
obtained for the contacts of the ligands with the hydrophobic residues Phe266 and Trp280 and polar 
Asn174 and Asn212. Finally, an important interaction was established between the central core of the 
ligands and the side chain of residue Lys98, which is mainly hydrophobic except for compound 1 that 
forms a hydrogen bond with one of the oxygen atoms in the succinimide-like central moiety. 
 
Effects of cytotoxicity and enhancement of MMS on human cell 
The presented data suggested that those 6 compounds can potently and selectively inhibit Ape1 in vitro. 
However, in order to have a general utility as BER inhibitors, it is important to confirm that they can block 
Ape1 function in living cells. The colony forming assay was used in order to study the capability of 
compounds 1 to 6 to enhance MMS cytotoxicity in HOS cells.[11, 20b, 21, 23, 44] MMS creates base damage 
by methylation, which is either lost spontaneously or excised by the alkylpurine DNA glycolsylase, 
resulting in a high number of cytotoxic abasic sites.[45] Inhibition of Ape1 in cell culture or the expression 
of a dominant negative form of the protein has been shown to increase sensitivity of human cells to 
MMS.[11, 20b, 21, 23, 44]  
 Cells were incubated with the 6 compounds before, during and after MMS treatment to ensure that 
inhibitors were present during the entire period of time needed for DNA damage to be formed. We 
analyzed the colony formation efficiency of HOS cells exposed to MMS alone, each inhibitor alone, or 
the combination of MMS plus inhibitor, compared to a non-exposed control. MMS alone reduced the 
number of colonies by 15% and, as shown in Figure 7, all six compounds enhance MMS cytotoxicity. 
Compounds 1 and 3 are less effective sensitizing tumoral cell to MMS than the rest, requiring a 
concentration up to 100 µM in order to obtain a 50% increase in cell killing. This lower sensitizing effect 
of compound 3 is consistent with its slightly smaller in vitro affinity for Ape1. However, the inefficiency of 
compound 1 was unexpected on the basis of its high ability to inhibit Ape1 activity in vitro. This 
observation suggested that it may not be able to cross cell membranes or it could be degraded before 
reaching its final target. Compound 4 had almost no effect on the cytotoxicity produced by MMS, only a 
little decrease in cell survival was observed at 50 µM, which was not incremented when cells were 
incubated with higher concentrations of this compound. Compound 5 exhibited an increasing capability 
to enhance the killing effect of MMS with an EC50 value around 50 µM, which is close to the IC50 value 
obtained in the in vitro experiments. Compound 6 showed a promising lethality (around 50 µM ), even if 
at higher concentrations it was unable to increase the effect of MMS in the cells.  
 The combination of MMS and compound 2 presented the best result in vivo. Its lethality was found 
to be in the lower micromolar range (7.5 µM), being consistent with its affinity for Ape1 in vitro. The 
results observed for this lead compound opens the door for their further optimization as Ape1 inhibitors. 
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Scheme 1. Flowchart of the virtual screening procedure applied in this work. 
 
Figure 1. Inside view of the active site of Ape1 with the ligand negative spheres image 
computed with GAGA. 
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Figure 2. Concentration curve showing the inactivation of human apurinic/apirimidinic endonuclease 
Ape1 by compounds 1 to 6. Remaining Ape1 activity vs. compound concentration was plotted, relative to 
untreated control samples. The effect of the compound solvent (DMSO) on Ape1 activity is showed in a 
continuous line. Dotted line marks 50% remaining Ape1 activity. Compounds 1 to 3 show inhibitory effect 
on Ape1 activity in the lower micro molar range. Compounds 4 to 6 show inhibitory effect on Ape1 
activity in the medium micro molar range. Each graph represents the average of triplicates of three 
separate experiments. 
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Figure 3. Chemical structures of the six compounds that showed Ape1 inhibition in the micro 
molar range. 
 
Figure 4. ThO inhibitor displacement assays. A ThO competition assay was used to evaluate the ability 
to bind DNA of all the Ape1 compounds which were active in the in vitro assay (1, 2, 3, 4, 5 and 6). No 
decrease in ThO fluorescence was observed upon the addition of the compounds, indicating that these 
compounds do not bind DNA. Mitoxantrone a clear DNA-binding molecule was used as positive control 
(filled squares). Fluorescence signal was normalized against DNA. 
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Figure 5. Complex formation identified by Mass spectrometry. Ape1 (28 µM) was mixed with each 
inhibitor (140 µM) on 100 mM ammonium acetate buffer and let to equilibrate at 4ºC for one hour as 
described in Materials and Methods. A) ESI-MS spectra of a) Ape1 b) Ape1 with compound 5 c) Ape1 
with compound 6 and d) Ape1 with compound 1. B) Zoom of the complex regions: a) Ape1 with 
compound 6 and b) Ape1 with compound 1.  
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Figure 6. Effect of compounds 1 to 6 in HOS cells survival, relative to untreated cells. Light grey bars 
show samples with no MMS added in the presence of different concentrations of each of the 6 
compounds, dark grey bars show the same experiment in the presence of MMS at 300 µM. MMS alone 
reduced the cell number to an average of 15%. Each graphic represents the average of duplicates of 
three separate experiments.  
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Figure 7. Average minimized structure of the compound 2-Ape1 complex after the molecular dynamics 
simulations. The color code is as follows: the protein is represented as cartoons in cyan. The side chains 
of main interacting residues are colored by atom type: C in cyan, N in blue, and O in red. In compound 2, 
C atoms are in orange, N in blue, O in red and the S atom in yellow. Hydrogen atoms are omitted for 
clarity. The gray sphere represents the Mg2+. Dashed lines correspond to the hydrogen bond interactions. 
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Table 1. List of the 15 top-ranked compounds obtained in the virtual screening . The computed chemical 
properties (as found in the ZINC database and the in vitro and in vivo activities of the active compounds 
are shown.  aMW molecular weight; bAverage interaction energy during the MD simulation in kcal/mol; cin 
vitro IC50 value (concentration of compound required to produce a 50% reduction in Ape1 activity). din 
vivo EC50 value (concentration of compound required to produce a 50% of cell killing in the presence of 
300 µM MMS). fND not determined. *The IC50 and the EC50 values represented the average of three 
separate experiments. 
ZINC id Log P H-bond H-bond Charge M W IC50 (µM)c* EC50 (µM)d*
donors acceptors
1    ZINC08790444 1,57 3 10 0 497,89 2,9 ± 0,55 >100
2    ZINC09086704 1,82 0 9 0 497,54 5 ± 0,55 7,5
3    ZINC00708759 6,37 0 9 -1 543,58 16,96 ± 0,64 >50
4    ZINC00870176 6,39 0 9 -1 543,58 38,5 ± 0,80 >100
5    ZINC00730105 4,79 1 8 -1 487,56 51,76 ± 0,86 (10-50)
6    ZINC02118845 1,97 2 8 -1 473,51 55,55 ± 0,80 50
7    ZINC04059809 5,19 0 8 -1 427,48 > 130 ND
8    ZINC08854784 2,61 0 12 0 477,50 >150 ND
9    ZINC08877288 2,12 3 9 -1 493,58 > 150 ND
10    ZINC04060698 4,63 0 8 -1 413,45 > 150 ND
11    ZINC03583501 3,69 0 9 0 523,95 > 200 ND
12    ZINC08932744 3,48 2 6 0 440,52 > 200 ND
13   ZINC09042551 1,91 3 9 -1 423,45 > 200 ND
14    ZINC04202254 3,97 0 8 -1 456,53 > 200 ND
15     ZINC00706278 2,61 0 8 -1 421,41 > 200 ND
 
 
Table 2. Interaction energy analysis as computed from the molecular dynamics simulations by the 
MMGBSA approach, for the six active molecules found in this work. All values are in kcal/mol. 
Compounds
Residue 1 2 3 4 5 6
Lys98 -1.75 -0.3 -5.97 -1.93 -4.85 -1.94
Tyr128 -0.23 -0.13 -0.16 -0.87 -1.99 -0.53
Asn174 -0.3 -2.45 -2.56 -1.98 -3.23 -0.34
Arg177 -3.91 -0.3 -2.81 -7.47 -4.25 -5.42
Asn212 -0.34 -6.27 -1.85 -0.17 -1.49 -0.23
Phe266 -1.94 -3.04 -3.55 -1.51 -2.94 -1.09
Thr268 -1.2 -0.56 -1.92 -2.51 -1.38 -0.84
Tyr269 -3.38 -3.31 -0.38 -1.44 -0.03 -1.22
Trp280 -2.1 -1.31 -2.2 -1.43 -3.65 -0.04
Leu282 -0.68 -1.4 -1.02 -0.14 -0.78 -0.09
Asp308 -0.04 6.07 2.33 0.54 0.08 -3.46
His309 -0.31 -7.83 -0.66 -0.42 -0.47 -0.5
Mg2+ -59.51 -37.66 -41.01 -56.41 -60.33 -70.59
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Conclusion 
Several classes of inhibitors of Ape1 have been described previously. However, the specificity of some 
of these compounds for Ape1 remain unclear[25] or a bit controversial.[20b, 26] Here, we have applied 
docking-based virtual screening technique to select as hit compounds a concrete number of molecules 
(15 compounds) from a 4 million library, to become novel and more potent Ape1 inhibitors. Six of these 
molecules selected from the ZINC database were found to be active. In particular, two of them are 
single-digit micromolar inhibitors against purified Ape1 (similar or even more potent than prior reported 
inhibitors), with the capacity to potentiate the cytotoxity of a relevant DNA-damaging agent like MMS. 
The predicted binding modes highlighted the interaction with the metallic cation, which is the most 
important energetically, the hydrogen bonding with residues Asn174 and Asn212, and a network of 
hydrophobic contacts of the ligands with the Phe266 and Trp280. In the case of compound 2, the most 
important interactions with Ape1 are mainly established through the quinoxaline core.  
 In summary, novel compounds have been identified as potent leads of Ape1 DNA repair inhibition. 
The binding properties, cellular uptake and solubility of these compounds can be further optimized to 
produce a subfamily of candidates with improved pharmacological properties. This new generation of 
compounds could lead to innovative drugs that may act as coadjuvants in cancer chemotherapy.  
Experimental Section 
Materials.  
The Ape1 gene (Homo sapiens) inserted into the pOTB7 vector was obtained from the Genomics Unit 
(Clone id: IMAGE 2823545) at the Centro Nacional de Investigaciones Oncologicas (CNIO). The pet28a 
plasmid and the competent Escherichia coli strains (DH5α, BL21(DE3), Rosetta) were purchased from 
Novagen. The enzymes and their corresponding buffers for cloning were purchased from Fermentas or 
New England Biolabs. The chemical reagents used for the expression and purification steps were 
purchased from Sigma, Merck, Bio-Rad or Fluka, and the SDS-PAGE standards, gels and buffers, from 
Invitrogen. HiTrap FF and size exclusion (HiLoad Superdex 75 16/60) columns were purchased from GE 
Healthcare.  
 The oligonucleotides 5’-FAM-GAGAA[X]ATAGTCGCG-3’ and 3′-Q-CTCTTGTATCAGCGC-5′ (where 
FAM is Fluorescein, Q is Dabsyl and X is ribitol,[46] an abasic site analog (AP)) site were custom-made by 
Sigma. Candidate compounds were purchased from different companies, in particular compounds 1, 5 
and 6 were obtained from IBScreen; 2 was obtained from Enamine and compounds 3, 4 were obtained 
from Specs. Stock solutions were prepared by dissolving them in DMSO at a final concentration of 1 mM 
and kept at -20 ºC until further use. The fluorescence assay was carried out on a spectrofluorometer 
Multi-Detection microplate reader Biotek FLx800 and a Jasco FP6200, in optical 96-well reaction plates.  
Human osteosarcoma cells, (ATCC Number HOS) were cultured in RPMI 1640 medium (Gibco) 
supplemented with 10% fetal bovine serum (Invitrogen). Methylmethanosulfonate (MMS) was obtained 
from Sigma. 
Virtual Screening (VS). All VS calculations were performed within the automated platform VSDMIP[32] 
(Virtual Screening Data Management on an Integrated Platform), see Figure 1. For clarity, we briefly 
describe here the main steps comprising the protocol (Scheme 1). 
Receptor preparation. The crystal structure of 1HD7 (PDB ID code)[47] was selected as a receptor since 
no substantial differences were found in the active site amongst the available Ape1 structures and it 
presented the highest resolution structure (1.95 Ǻ). All atoms other than the receptor were deleted 
except for the divalent metal (Pb2+) in the active site, which in order to resemble in vivo conditions, was 
replaced by magnesium, the preferred metal cofactor of the human Ape1 enzyme.[48] AMBER8 ff99[49] 
force field was then used to assign atom types and charges for each atom in the receptor. Hydrogen 
atoms were added assuming standard protonation states of titratable groups, except for the key 
interacting residues, in which the hydrogen atoms were assigned based on the information given from 
the H++ web server.[50] 
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 For this purpose, the receptor was submitted to the server and a Generalized Born model was used for 
the pKa calculation at pH=6.5 with 0.15 M salt concentration and an internal and external dielectric 
constant of 4 and 80, respectively. The histidine residue His309, present in the binding site, was found to 
be protonated, which is consistent with an NMR study done by Lowry et al.[51] 
Binding site definition and characterization. To delimit the binding site PDB codes 1HD7[47] (Ape1 
apo form) and 1DEW[52] (Ape1 bound to DNA, subunit A) were superimposed, (RMSD among Cα carbon 
atoms ~0.28 Ǻ) selecting a DNA fragment as the core around which to build the docking box by adding a 
5.0 Å cushion to its maximum dimensions. This DNA fragment consists of an abasic sugar connected to 
a cytosine nucleotide residue to its 5’ end and including the following 5’ phosphate. An equally spaced 
grid of 0.375 Å was then built, and CGRID[36] was used to calculate receptor interaction fields, a 12-6 
Lennard-Jones term. The electrostatic term was modeled with a sigmoidal dielectric screening function 
using typical atom probes (C, H, N, O, S, P, F, Cl, Br, and I) at each grid point. Next benzene, water and 
methanol probes were docked with CDOCK[36] to generate intermolecular interaction energy maps aimed 
to capture the most favorable hydrophobic, hydrophilic and hydrogen bonds interaction areas, 
respectively. These areas were further compressed into Gaussian functions using GAGA algorithm,[53] 
producing a sort of negative image of the interaction site. The putative active ligands in the library must 
conform to this approximate shape.  
Chemical library preparation. Ligands for VS consisted of a library with more than 4 million (4,039,777) 
non-redundant molecules, obtained from the publicly available ZINC database[38] in SMILES format.[54] 
Multiple protonation states and tautomeric forms were considered as implemented by default in ZINC 
database.[39] The molecules were then processed within VSDMIP[32] as follows: a) conversion from 
SMILE to 3D MOL2 using CORINA,[55] b) atomic charges calculations with MOPAC[56] (MNDO ESP 
method) on every single structure provided by CORINA, and c) atom types assignment according to the 
AMBER ff99[49] force field and conformational analysis with ALFA.[57] 
Filter 1. An initial filter was performed with the docking program DOCK[35] to quickly discard those 
molecules that do not geometrically fit within the binding site. The spheres needed by DOCK were 
generated previously with GAGA. We used DOCK contact as scoring function, normalizing the score 
values (scorei) by converted them into ZScore using mean (average score) and standard deviation (σ) 
values (ZScorei = (scorei-average score)/σ). Only molecules with a ZScore beyond a cut off value of 4 
were selected and 2,500 passed onto the next step.  
Filter 2. Selected molecules from filter 1 were studied with the more accurate docking algorithm 
CDOCK.[36] CDOCK exhaustively docks each molecule within the binding site of the receptor using the 
interaction energy grids previously calculated with CGRID. This was achieved by an exhaustive 
exploration of the location and orientation of each molecule by positioning its centers of mass on grid 
points, where discrete rotations of 27º arc on each axe are performed. Finally, the energy for each pose 
was evaluated by the molecular mechanism force-field scoring function implemented in CDOCK, which 
besides including a 12–6 Lennard-Jones term and an electrostatic term modeled with a sigmoidal 
dielectric screening function, also accounts for ligand and receptor desolvations as well as for hydrogen 
bonding interactions.[58]  
Molecular dynamics simulations. The top ranked 100 molecules according to CDOCK’s scoring 
function were subjected to a more exhaustive binding free energy estimation by a combination of 
molecular dynamics (MD) trajectories and MM-GBSA[37] calculation on these trajectories. The 100 
complexes were hydrated by using boxes containing explicit water molecules, energy minimized, heated 
(20 ps), and equilibrated (100 ps). Then when the equilibration was reached, MD trajectories were 
continued for 2 ns. Structures were homogenously sampled at each ps and stored for post-processing. 
All the simulations were performed at constant pressure and temperature (1 atm and 300 K) with an 
integration time step of 2 fs. SHAKE[59] was used to constrain all the bonds involving H atoms at their 
equilibrium distances. Periodic boundary conditions and the Particle Mesh Ewald methods were applied 
to treat long-range electrostatic effects.[60] AMBER ff99[49] and TIP3P[61] force-fields were used in all 
cases. Finally, the effective binding free energies were qualitatively estimated with the MM-GBSA[37] 
approach, which calculates the free energy of binding as a sum of a Molecular Mechanics (MM) 
interaction term, a solvation contribution thorough a Generalized Born (GB) model and a Surface Area 
(SA) contribution to account for the non-polar part of desolvation. A 12–6 Lennard-Jones term was used 
 15 
to model de MM contribution. For GB, the solute dielectric constant was set to 4 while that of the solvent 
was set to 80, and the dielectric boundary was calculated using a solvent probe radius of 1.4 Å. The SA 
contribution was approximated as a linear relationship to the change in SASA (Solvent Accessible 
Surface Area): 
∆Gnp = a +b ∆SASA 
where a is 0.092 kcal·mol-1, b is 0.00542 kcal·mol-1Å-2, ∆Gnp is the SA contribution, and the change in 
SASA refers to the complex SASA minus the sum of that of the receptor and the ligand alone. In addition, 
interaction energy analysis between the ligands and the more relevant residues in the binding site were 
computed (with MM-GBSA) and are contained in Table 2. All the trajectories and analysis were 
performed using the AMBER 8 computer program and associated modules.[62] 
Selection of candidates. Among the 100 molecules with highest scoring values 15 were selected upon 
visual examination. All visualizations were done within the molecular graphics program PyMOL.[63] 
Averaged structures along the MD trajectories were obtained and minimized in vacuum with the ff99 
force field, without periodic boundary conditions and during 1000 steps (the first 500 with the steepest 
descent method and the rest with the conjugated gradient) solely to alleviate the possible clashes that 
may be originated by averaging the coordinates. These structures were used for graphical 
representation and comparison of the binding modes. Finally, those 15 selected compounds were 
purchased and tested experimentally. 
Inhibition of Ape1 Activity 
Protein Production and Purification. The in vitro assays were carried out using recombinant Ape1. 
The cDNA of full length Ape1 (IMAGE:2823545) was amplified by PCR using primers 5’-
CCCGGGCATATGCCGAAGCGTGGGAAAAAG-3’and 5’GCCCTCGAGTCACAGTGCTAGGTATAGG- 
GT-3’, that incorporated the NdeI and XhoI restriction enzymes sites respectively. The PCR product was 
cloned into the pet-28a(+) (Novagen) vector. The resulting construct, Ape1-pet28a, was verified by 
nucleic acid sequencing. The protein was expressed in the E. coli strain BL21 and once the culture 
reached an OD600 value of 0.6 it was induced by adding 1 mM IPTG during 3 h at 30 °C. The pellet from 
a 2 L culture was disrupted by sonication and centrifuged. The supernatant was filtered, loaded into a 
HiTrapTM FF column (GE Healthcare), and eluted with an Imidazole gradient. Finally, the protein was 
loaded into a Superdex 75 16/60 column (GE Healthcare), being the buffer 300 mM NaCl, 20 mM Tris 
pH 8.0, 1 mM DTT and 5% v/v glycerol. 
Ape1 Activity Assay. The in vitro AP site cleavage assay was carried out using a modified version of 
the protocol that had been described previously.[23, 28] Briefly, Ape1 enzyme (5,9 nM) was incubated with 
or without compounds (at 100 and 200 µM) in a buffer containing 50 mM Tris–HCl (pH 8.0), 1 mM MgCl2, 
5 mM NaCl and 2 mM dithiothreitol (DTT) at room temperature for 30 min. The sequence 5’-FAM-
GAGAA[X]ATAGTCGCG-3’ and its complementary oligonucleotide 3′-Q-CTCTTGTATCAGCGC-5′ were 
annealed to form a double stranded DNA and the reaction was initiated by addition of the annealed 
substrate. Fluorescence readings were taken continuously after 30 min incubation at 20°C, at excitatio n 
and emission wavelength of 485 and 535 nm, respectively. Hits from the initial screen were analyzed 
further for inhibitory potency using decreasing dilutions of inhibitor. Each compound concentration was 
assayed in triplicate and experiments repeated three times. Percent inhibition was calculated relative to 
untreated DMSO-control samples. Bovine serum albumin (BSA) was used as a negative control (data 
not shown). The IC50 values were determined graphically from plots of remaining activity vs. inhibitor 
concentration.  
DNA Intercalation Assay. A modified version of the ethidium bromide-based DNA binding assay was 
carried out essentially as described previously.[30, 40] In brief, a mixture of 500 nM of unlabeled double 
stranded DNA and 2.5 µM ThO in Ape1 reaction buffer in 400 ul total volume was prepared. Compounds 
(at concentrations in the range of 100 pM to 100 µM) were added, and the fluorescence signal (excitation 
501 nm and emission 530 nm) was measured after 10 minutes of incubation at room temperature in 50 
mM Tris-HCl, pH 7.5, 50 mM NaCl, 10 mM MgCl2 and 1 mM EDTA. Each compound concentration was 
assayed in triplicates. Percentage fluorescence was calculated relative to the total fluorescence acquired 
with double stranded DNA and 2.5 µM ThO.  
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Mass analysis of the non-covalent complex between Ape1 and lead compounds. Mass 
spectrometry experiments were performed on Waters (Manchester, UK) instrument equipped with 
electrospray ionisation, a travelling wave ion mobility cell and a time-of-flight mass analyser. Synapt G1 
was interfaced to a chip-based nanoESI device, (Advion, Triversa Nanomate). This device contains a 96 
-well sample plate, 96 disposable spraying tips and an ESI chip with 100 nozzles in front of the inlet of 
the mass spectrometer. The instrument was operated in the automatic mode using a contact closure 
signal. A spraying voltage of +1.76 kV and a sample pressure of 5.80 psi were applied. Each well was 
loaded with 10µl of sample, from which a total of 4 µl was infused during 10 min. Operating conditions for 
the Synap G1 mass spectrometer were: cone voltage = 20V; extraction cone = 5.5 V; source 
temperature = 20 ºC; trap and transfer voltages = 6 V and 4V, respectively. The ion mobility cell was 
filled with N2 and an electric field was applied to the cell in the form of waves (wave height = 9.5 V) that 
passed thought the cell at 300 m/s. The bias voltage for ion introduction into the IMS cell was 15V. 
The Ape1 buffer was exchanged to 100 mM ammonium acetate pH=7 to prevent buffer interferences in 
the mass spectrometry experiments. Once we confirmed the mass spectrum for the native form of Ape1, 
we proceeded to analyze the non-covalent inhibitor-protein complexes. Ape1 (28 µM) was mixed with 
(140 µM of) each inhibitor (1 to 6) separately and let to equilibrate at 4ºC for one hour. Ape1 in the 
presence of DMSO or an inactive molecule (16) were used as Mass spectrum controls. 
Cell culture cytotoxic assay. The effect of compounds 1 to 6 on the sensitivity of human osteosarcoma 
cells (HOS) to methyl methanesulfonate (MMS) was determined using colony formation assays as it has 
been previously described in Ape1 inhibition studies[28]. HOS cells were seeded at 10 x 103 cells per well 
density in 24-well, flat-bottomed plates and incubated in a humidified, 5% CO2 incubator at 37oC for 36 h. 
Compound solutions were diluted in the culture medium at final concentrations of 100, 50, 30, 20, 5, 2.5 
and 1 µM, and were immediately used to treat the cells. Cells were incubated with these compounds’ 
solutions for 6 h and then MMS (or the equivalent volume of the vehicle as negative controls) was added 
to a final concentration of 300 µM. After 2 h of incubation, the medium was replaced with fresh medium 
containing the same compound concentration, and cells were left to grow for an additional 16 h. The 
cells were then replated at densities of 2000 cells per well in 24-well plates and grown for 1 week until 
discrete colonies were formed. Colonies were washed twice with PBS and stained with a 0.5% crystal 
violet - 20% ethanol solution. Cells were rinsed with deionized water and air dried. Stained colonies were 
counted in a ELx 800 Universal Microplate Reader (Bio-Tek Instruments INC) and clonogenic survival 
was determined relative to untreated cells. Samples were assayed in duplicates and experiments 
repeated three times. 
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GRAFICAL ABSTRACT 
 
Rational design. Here we report the identification by docking-based virtual screening of six compounds 
as potential Ape1 inhibitors. These compounds showed inhibitory activity in vitro in the low-medium µM 
range and they also potentiated the cytotoxicity of MMS in fibrosarcoma cells. This study opens the door 
to the development of a new generation of Ape1 inhibitors. 
 
 
 
 
 
